“In 2026 we look to expand penetration of international markets with our MCM biodefense business, maintain market leadership across the naloxone category and offer new innovative solutions, pursue organic and inorganic growth opportunities that align with our internal capabilities, and remain disciplined on operational efficiencies,” said CEO Joe Papa.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions reports Q4 EPS (43c) vs. 5c last year
- Emergent BioSolutions announces up to C$140M in Canadian contracts
- Emergent BioSolutions authorizes $50M stock repurchase program
- Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround
- EBS Earnings Report this Week: Is It a Buy, Ahead of Earnings?